Henry Schein Inc (HSIC) Stock Analysis and Metrics

Henry Schein

NASDAQ: HSIC

$85.95 ▲ +0.48 (+0.56%)

At close: Jul 27, 2026 · 10:31 AM UTC

Financial Ratios

Market Cap9.87 Bn

P/E24.14

P/S0.74

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)3.37 Bn

Revenue Growth (1y) (Qtr)6.31

Add ratio to table…

About

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. The company distributes health care products and services primarily to office based dental and medical practitioners and alternate sites of care. It serves more than 1,000,000 customers worldwide across dental practices laboratories physician practices ambulatory surgery centers government institutional health care clinics home health providers and other alternate care facilities. With over 90 years of experience in the health care distribution sector the firm has built a broad base of small mid sized and large customers.

The company generates revenue through the sale of over 300,000 branded and private label products including consumables equipment and pharmaceuticals. It also offers value added services such as financial solutions continuing education consulting and practice management support. Revenue is divided among three reportable segments with the majority coming from the Global Distribution and Value Added Services segment which accounted for about 84.5% of consolidated net sales in the most recent fiscal year. The Global Specialty Products segment contributed roughly 11.7% while the Global Technology segment represented approximately 5.1%.

The company operates through the following segments: Global Distribution and Value Added Services Global Specialty Products and Global Technology. These segments are defined by function rather than geography.

• Global Distribution and Value Added Services: This segment distributes national brand and corporate brand merchandise equipment and technical services to the global dental and medical markets and provides value added services including financial services continuing education consulting and practice services. It also markets a portfolio of cost effective high quality consumable merchandise under its own corporate brand.

• Global Specialty Products: This segment manufactures markets and sells dental implant and biomaterial products endodontic orthodontic and orthopedic products and other health care related products and services. It operates manufacturing facilities in the United States Switzerland Germany Brazil and France and sells its products in approximately 90 countries.

• Global Technology: This segment develops and distributes practice management software e services and other technology enabled products to health care providers. As of the latest reporting date the platform served an active user base of approximately 95,000 practices and 324,000 consumers.

Henry Schein, Inc. is widely regarded as the world's largest provider of health care products and services to office based dental and medical practitioners. Its competitive strengths include a broad product line, extensive e commerce capabilities, strong customer service, and a suite of value added solutions that enable it to be a single source of supply for many customers. Key competitors in the United States dental distribution market are Patterson Dental, a division of Patterson Companies Inc, and Benco Dental Supply Company. In the United States medical distribution market the primary competitors are McKesson Corporation, and Medline Industries Inc. Outside the United States, the company faces mainly local and regional distributors and believes it is the only global distributor of supplies and equipment to dental practices. Within Global Specialty Products it competes with companies such as Straumann, Envista, Zimvie, and Dentsply Sirona for dental implants and with Geistlich Pharma AG, and Botiss Biomaterials GmbH in the biomaterials market. In Global Technology it competes with various dental software providers including the Eaglesoft division of Patterson Companies Inc, Carestream Dental LLC, Centaur Software Development Co Pty Ltd trading as dental4windows dental4web, Open Dental Software Inc, PlanetDDS LLC, Good Methods Global Inc trading as CareStack, Curve Dental LLC, the NextGen division of Quality Systems Inc, eClinicalWorks, and Epic Systems Corporation. The company’s scale integrated logistics network and focus on customer service give it a distinct advantage in a fragmented and competitive industry.

The company serves more than 1,000,000 customers worldwide including dental practices laboratories physician practices ambulatory surgery centers government institutional health care clinics home health providers and other alternate care facilities. Its customer base spans small independent offices large group practices dental support organizations and integrated delivery networks as well as public sector agencies and private enterprises that require reliable supply of health care products and services.

Investment Thesis

▲ Bull case

Henry Schein is effectively leveraging its BOLD+1 strategy to capture high-growth opportunities in value implants and AI-integrated practice management software, which are outperforming core segments and represent a structural shift rather than a temporary uptick. The company’s S.I.N. 360 acquisition provides greater control over the faster-growing value implant market, where growth is outpacing premium implants due to strong clinical engagement and demand for cost-effective solutions in both U.S. and international markets. This is further reinforced by the success of the BioHorizons Global Symposium, which highlighted innovations in tissue regeneration and digital workflows, signaling sustained demand for advanced yet affordable implant systems. Simultaneously, Henry Schein One’s next-generation AI clinical workflow launched at Thrive Live generated significant excitement, with over 1,000 attendees and strong traction in cloud-based software subscriptions, which grew roughly 25% year-over-year to exceed 13,000 Dentrix Ascend and Dentale users. These initiatives are not incremental improvements but foundational enhancements to the company’s platform, increasing switching costs and deepening customer integration. Management’s focus on accelerating the leverage priority of BOLD+1 ensures these high-margin, high-growth businesses—which are already approaching 50% of total operating income—will continue to expand, driving earnings growth beyond what current guidance reflects. The market may be underestimating the compounding effect of these technology and specialty investments, which improve customer retention, increase wallet share, and create defensible revenue streams less vulnerable to cyclical downturns in procedural volumes.
Operational improvements from value creation initiatives are delivering earlier-than-expected margin expansion and are poised to accelerate in the second half of 2026, creating a meaningful inflection point for profitability that is not fully priced into the stock. Gross margin improved by 25 basis points year-over-year and 86 basis points versus Q4 2025, driven by early benefits from gross profit initiatives, favorable product mix from corporate brand growth, and dynamic pricing responsiveness—all of which are scalable and sustainable. The company is on track to achieve a $125 million run rate in annual operating income improvement by year-end, with benefits weighted toward the back half of the year as G&A cost reductions from centralized back-office functions and indirect procurement savings begin to materialize. These are not one-time restructuring gains but enduring capability builds: new value pricing techniques, corporate brand expansion, and supply chain efficiencies will persist beyond 2026, supporting long-term margin expansion. With high-growth, high-margin businesses growing faster and contributing increasingly to operating income, Henry Schein is positioned to deliver high single-digit to low double-digit earnings growth without relying on episodic cost-cutting programs. The market may be overlooking how these initiatives de-risk earnings volatility while simultaneously funding growth investments in AI and software, creating a self-reinforcing cycle of innovation and profitability.
Henry Schein’s dominant position with national DSOs and its ability to support their growth through exclusive supplier partnerships, technology integration, and operational efficiency represents a durable competitive advantage that is underappreciated in current valuations. DSOs are gaining market share faster than the overall dental market, and Henry Schein benefits directly as their primary distributor, leveraging its scale, overnight delivery reliability, and deep relationships to capture disproportionate growth. Management confirmed that DSO leaders value Henry Schein’s national support, technology-enabled profitability improvements, and access to market-exclusive products—factors that are difficult for competitors to replicate. This relationship is further strengthened by the company’s global e-commerce platform, henryschein.com, which is now processing over 80% of U.S. dental e-commerce sales and will be fully rolled out by end-August 2026, with international expansion to follow. The platform enhances customer stickiness, reduces friction in ordering, and provides valuable data analytics to improve inventory turnover and service levels. As DSOs continue to consolidate and invest in equipment and digital workflows—evidenced by strong traditional equipment growth and rising demand for intraoral scanners—Henry Schein’s integrated platform becomes increasingly essential. The market may be failing to recognize that this DSO-driven growth engine is structural, not cyclical, and will sustain above-market revenue expansion even in modest macro environments.

Henry Schein is effectively leveraging its BOLD+1 strategy to capture high-growth opportunities in value implants and AI-integrated practice management software, which are outperforming core segments and represent a structural shift rather than a temporary uptick. The company’s S.I.N. 360 acquisition provides greater control over the faster-growing value implant market, where growth is outpacing premium implants due to strong clinical engagement and demand for cost-effective solutions in both U.S. and international markets. This is further reinforced by the success of the BioHorizons Global Symposium, which highlighted innovations in tissue regeneration and digital workflows, signaling sustained demand for advanced yet affordable implant systems. Simultaneously, Henry Schein One’s next-generation AI clinical workflow launched at Thrive Live generated significant excitement, with over 1,000 attendees and strong traction in cloud-based software subscriptions, which grew roughly 25% year-over-year to exceed 13,000 Dentrix Ascend and Dentale users. These initiatives are not incremental improvements but foundational enhancements to the company’s platform, increasing switching costs and deepening customer integration. Management’s focus on accelerating the leverage priority of BOLD+1 ensures these high-margin, high-growth businesses—which are already approaching 50% of total operating income—will continue to expand, driving earnings growth beyond what current guidance reflects. The market may be underestimating the compounding effect of these technology and specialty investments, which improve customer retention, increase wallet share, and create defensible revenue streams less vulnerable to cyclical downturns in procedural volumes.
Operational improvements from value creation initiatives are delivering earlier-than-expected margin expansion and are poised to accelerate in the second half of 2026, creating a meaningful inflection point for profitability that is not fully priced into the stock. Gross margin improved by 25 basis points year-over-year and 86 basis points versus Q4 2025, driven by early benefits from gross profit initiatives, favorable product mix from corporate brand growth, and dynamic pricing responsiveness—all of which are scalable and sustainable. The company is on track to achieve a $125 million run rate in annual operating income improvement by year-end, with benefits weighted toward the back half of the year as G&A cost reductions from centralized back-office functions and indirect procurement savings begin to materialize. These are not one-time restructuring gains but enduring capability builds: new value pricing techniques, corporate brand expansion, and supply chain efficiencies will persist beyond 2026, supporting long-term margin expansion. With high-growth, high-margin businesses growing faster and contributing increasingly to operating income, Henry Schein is positioned to deliver high single-digit to low double-digit earnings growth without relying on episodic cost-cutting programs. The market may be overlooking how these initiatives de-risk earnings volatility while simultaneously funding growth investments in AI and software, creating a self-reinforcing cycle of innovation and profitability.
Henry Schein’s dominant position with national DSOs and its ability to support their growth through exclusive supplier partnerships, technology integration, and operational efficiency represents a durable competitive advantage that is underappreciated in current valuations. DSOs are gaining market share faster than the overall dental market, and Henry Schein benefits directly as their primary distributor, leveraging its scale, overnight delivery reliability, and deep relationships to capture disproportionate growth. Management confirmed that DSO leaders value Henry Schein’s national support, technology-enabled profitability improvements, and access to market-exclusive products—factors that are difficult for competitors to replicate. This relationship is further strengthened by the company’s global e-commerce platform, henryschein.com, which is now processing over 80% of U.S. dental e-commerce sales and will be fully rolled out by end-August 2026, with international expansion to follow. The platform enhances customer stickiness, reduces friction in ordering, and provides valuable data analytics to improve inventory turnover and service levels. As DSOs continue to consolidate and invest in equipment and digital workflows—evidenced by strong traditional equipment growth and rising demand for intraoral scanners—Henry Schein’s integrated platform becomes increasingly essential. The market may be failing to recognize that this DSO-driven growth engine is structural, not cyclical, and will sustain above-market revenue expansion even in modest macro environments.

▼ Bear case

Henry Schein’s medical distribution segment remains vulnerable to unpredictable demand swings tied to public health trends, and the company’s reliance on mitigating strategies for macroeconomic headwinds like oil prices introduces margin volatility that is not being adequately priced in by investors. The first quarter saw a decline in point-of-care diagnostic test product sales due to a light flu season—a category representing 15% to 20% of the medical business— which offset strong growth in Home Solutions and dialysis, resulting in only 1.3% U.S. medical distribution sales growth. While management notes that excluding this category would have yielded mid-single-digit growth, the unpredictability of respiratory illness seasons creates recurring earnings volatility that is difficult to forecast and hedge effectively. Furthermore, the company’s guidance assumes it can mitigate the impact of rising oil prices on freight and product costs, but offers no concrete sensitivity analysis or threshold (e.g., oil above $100 per barrel) beyond stating that mitigation measures are in place. This lack of transparency raises concerns about margin resilience if energy costs persistently rise or if supply chain disruptions amplify freight expenses. The medical segment’s dependence on nonacute care settings, while structurally favorable, does not insulate it from external shocks like pandemics, policy shifts (e.g., Medicaid work requirements), or sudden changes in diagnostic testing demand—factors that could recur and undermine the stability of otherwise steady growth in Home Solutions and dialysis.
The company’s share repurchase program, while supportive of EPS, is consuming a significant portion of free cash flow and may be constraining reinvestment in organic growth initiatives, particularly given the modest internal sales growth trends across key segments. Henry Schein repurchased 1.6 million shares for $125 million in Q1 2026, leaving $655 million authorized but raising questions about capital allocation priorities when internal sales growth was only 2.5% on a local currency basis. U.S. dental merchandise sales grew 4.1% internally, international dental merchandise just 1.8%, and specialty products only 1.7%—figures that suggest organic demand is weaker than headline sales growth implies, with the difference made up by acquisitions (0.7%), foreign exchange (3.1%), and value-added services strength. While value creation initiatives are expected to drive margin expansion, they do not directly address the need for top-line growth from innovation or market expansion. Continued reliance on buybacks to boost EPS could signal a lack of confidence in internal investment opportunities, especially if returns on those initiatives fail to materialize as expected. Investors may be overlooking the risk that financial engineering is substituting for genuine operational growth, which could become problematic if macro conditions worsen or if value creation benefits fall short of the $200 million target.
Growth in Henry Schein’s Global Specialty Products Group is being skewed by a favorable shift toward lower-margin value implants, which is improving volume but pressuring gross margin and may not be sustainable if premium implant demand does not recover. The segment reported 8.1% sales growth (1.7% local currency), driven by high single-digit value implant growth, but management acknowledged that the sales mix shift toward value implants resulted in lower gross margin versus the prior year. Premium implant demand remained flat to down, particularly in the U.S., with only low single-digit to flat growth in Europe—indicating potential weakness in higher-margin, procedure-driven segments that are more sensitive to economic cycles and patient willingness to pay for elective treatments. While value implants offer volume growth and access to cost-conscious segments, they inherently carry lower margins, and the company’s increasing reliance on this mix could cap overall profitability in the specialty business. Furthermore, the long-term success of this strategy depends on whether value implant adoption translates into broader ecosystem opportunities (e.g., digital workflows, AI integration) or remains a commoditized volume play. If premium implant demand does not rebound and value implants become a margin-dilutive staple, the Specialty Products Group may struggle to deliver the high-margin contribution implied by the BOLD+1 strategy’s goal of reaching 50% of operating income from high-growth, high-margin businesses by 2027.

Henry Schein’s medical distribution segment remains vulnerable to unpredictable demand swings tied to public health trends, and the company’s reliance on mitigating strategies for macroeconomic headwinds like oil prices introduces margin volatility that is not being adequately priced in by investors. The first quarter saw a decline in point-of-care diagnostic test product sales due to a light flu season—a category representing 15% to 20% of the medical business— which offset strong growth in Home Solutions and dialysis, resulting in only 1.3% U.S. medical distribution sales growth. While management notes that excluding this category would have yielded mid-single-digit growth, the unpredictability of respiratory illness seasons creates recurring earnings volatility that is difficult to forecast and hedge effectively. Furthermore, the company’s guidance assumes it can mitigate the impact of rising oil prices on freight and product costs, but offers no concrete sensitivity analysis or threshold (e.g., oil above $100 per barrel) beyond stating that mitigation measures are in place. This lack of transparency raises concerns about margin resilience if energy costs persistently rise or if supply chain disruptions amplify freight expenses. The medical segment’s dependence on nonacute care settings, while structurally favorable, does not insulate it from external shocks like pandemics, policy shifts (e.g., Medicaid work requirements), or sudden changes in diagnostic testing demand—factors that could recur and undermine the stability of otherwise steady growth in Home Solutions and dialysis.
The company’s share repurchase program, while supportive of EPS, is consuming a significant portion of free cash flow and may be constraining reinvestment in organic growth initiatives, particularly given the modest internal sales growth trends across key segments. Henry Schein repurchased 1.6 million shares for $125 million in Q1 2026, leaving $655 million authorized but raising questions about capital allocation priorities when internal sales growth was only 2.5% on a local currency basis. U.S. dental merchandise sales grew 4.1% internally, international dental merchandise just 1.8%, and specialty products only 1.7%—figures that suggest organic demand is weaker than headline sales growth implies, with the difference made up by acquisitions (0.7%), foreign exchange (3.1%), and value-added services strength. While value creation initiatives are expected to drive margin expansion, they do not directly address the need for top-line growth from innovation or market expansion. Continued reliance on buybacks to boost EPS could signal a lack of confidence in internal investment opportunities, especially if returns on those initiatives fail to materialize as expected. Investors may be overlooking the risk that financial engineering is substituting for genuine operational growth, which could become problematic if macro conditions worsen or if value creation benefits fall short of the $200 million target.
Growth in Henry Schein’s Global Specialty Products Group is being skewed by a favorable shift toward lower-margin value implants, which is improving volume but pressuring gross margin and may not be sustainable if premium implant demand does not recover. The segment reported 8.1% sales growth (1.7% local currency), driven by high single-digit value implant growth, but management acknowledged that the sales mix shift toward value implants resulted in lower gross margin versus the prior year. Premium implant demand remained flat to down, particularly in the U.S., with only low single-digit to flat growth in Europe—indicating potential weakness in higher-margin, procedure-driven segments that are more sensitive to economic cycles and patient willingness to pay for elective treatments. While value implants offer volume growth and access to cost-conscious segments, they inherently carry lower margins, and the company’s increasing reliance on this mix could cap overall profitability in the specialty business. Furthermore, the long-term success of this strategy depends on whether value implant adoption translates into broader ecosystem opportunities (e.g., digital workflows, AI integration) or remains a commoditized volume play. If premium implant demand does not rebound and value implants become a margin-dilutive staple, the Specialty Products Group may struggle to deliver the high-margin contribution implied by the BOLD+1 strategy’s goal of reaching 50% of operating income from high-growth, high-margin businesses by 2027.

Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Distribution

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	MCK	Mckesson Corp	104.92 Bn	20.58	0.26	6.56 Bn
2	COR	Cencora, Inc.	60.29 Bn	23.62	0.18	12.39 Bn
3	CAH	Cardinal Health Inc	53.82 Bn	34.77	0.21	8.92 Bn
4	HSIC	Henry Schein Inc	9.87 Bn	24.14	0.74	3.37 Bn
5	AHG	Akso Health Group	3.19 Bn	-	-	0.00 Bn
6	YI	111, Inc.	0.66 Bn	-71.09	0.38	0.03 Bn
7	ACH	Accendra Health Inc/Va/	0.25 Bn	-0.25	0.09	2.10 Bn
8	FOCL	Edap Tms Sa	0.23 Bn	-7.37	3.10	0.02 Bn

Research Tools

Developers

About

Investment Thesis

Breakdown of Revenue (2025)

Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Breakdown of Revenue (2025)

Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password